Scarica l'app Stockscreener
17.43
24.23%
3.40
Dopo l'orario di chiusura:
17.69
0.26
+1.49%
Terns Pharmaceuticals Inc Borsa (TERN) Ultime notizie
Terns Pharmaceuticals announces data from CARDINAL trial of TERN-701 - MSN
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) - The Manila Times
Terns Pharma (NASDAQ: TERN) awards 252,500 options under Nasdaq Rule 5635(c)(4) - Stock Titan
Terns Pharmaceuticals stock hits 52-week high at 16.41 USD By Investing.com - Investing.com Philippines
Henry Schein, Sanmina, Wingstop, Waters And Other Big Stocks Moving Higher On Tuesday - Benzinga
Terns Pharma (TERN) Receives Price Target Raise to $28 by Truist - GuruFocus
Truist Financial Maintains Terns Pharmaceuticals(TERN.US) With Buy Rating, Announces Target Price $28 - 富途牛牛
Terns Pharmaceuticals stock extends gain after positive CML drug data By Investing.com - Investing.com Canada
Terns Pharmaceuticals stock price target raised to $22 at BMO on strong ASH data - Investing.com Nigeria
Terns Pharmaceuticals stock extends gain after positive CML drug data - Investing.com
Terns Pharmaceuticals stock hits 52-week high at 16.41 USD - Investing.com
Terns Pharma (TERN): Barclays Raises Price Target by 92.86% | TE - GuruFocus
Mizuho Boosts Price Target on Terns Pharmaceuticals to $32 From $9, Keeps Outperform Rating - MarketScreener
Terns reports 64% MMR rate in phase 1 CML trial with TERN-701 - Investing.com Australia
Terns Pharmaceuticals (TERN) Upgraded with Increased Price Targe - GuruFocus
Terns Pharmaceuticals (TERN) Upgraded with Increased Price Target Following Promising Data - GuruFocus
Terns Pharmaceuticals stock rating upgraded to Buy by H.C. Wainwright - Investing.com
Terns Pharma (TERN) Upgraded to Buy by HC Wainwright & Co. | TER - GuruFocus
Terns Pharmaceuticals stock price target raised by Truist on CML drug data - Investing.com South Africa
William Blair Upgrades Terns Pharmaceuticals (TERN) - Nasdaq
Price momentum metrics for Terns Pharmaceuticals Inc. explainedEarnings Risk Report & AI Powered Trade Plan Recommendations - newser.com
Relative strength of Terns Pharmaceuticals Inc. in sector analysisMarket Performance Recap & Weekly Return Optimization Alerts - newser.com
Terns Pharmaceuticals (TERN) Is Up 74.1% After Positive Phase 1 TERN-701 Data in CML Patients - Yahoo Finance
Combining price and volume data for Terns Pharmaceuticals Inc.Dollar Strength & Growth Oriented Trade Recommendations - newser.com
How sentiment analysis helps forecast Terns Pharmaceuticals Inc.Quarterly Growth Report & Verified Short-Term Trading Plans - newser.com
What does recent volatility data suggest for Terns Pharmaceuticals Inc.Trade Volume Summary & Free Growth Oriented Trading Recommendations - newser.com
Terns Pharmaceuticals (TERN) Pivots After TERN-601 Setback Can a Focus on Oncology Redefine Its Future? - simplywall.st
After GLP-1 drug falters, Terns Pharmaceuticals shifts focus to cancerBizwomen - The Business Journals
Biotech Deals And Breakthroughs Spark Heavy Trading Across Markets - Finimize
How Terns Pharmaceuticals Inc. stock reacts to Fed rate cutsQuarterly Portfolio Summary & Weekly High Return Stock Opportunities - newser.com
Oppenheimer raises Terns Pharmaceuticals stock price target to $24 on promising leukemia drug data By Investing.com - Investing.com South Africa
Terns Pharma (TERN) Upgraded to Outperform by William Blair | TE - GuruFocus
Oppenheimer raises Terns Pharmaceuticals stock price target to $24 on promising leukemia drug data - Investing.com Australia
William Blair upgrades Terns Pharmaceuticals stock rating to Outperform By Investing.com - Investing.com South Africa
Pharmaceutical Stocks To Add to Your WatchlistNovember 3rd - MarketBeat
Terns Pharmaceuticals' Leukemia Drug Seen As Potential Disruptor In CML Treatment Landscape, Analyst Upgrades - Benzinga
Terns reports 64% MMR rate in phase 1 CML trial with TERN-701 By Investing.com - Investing.com South Africa
William Blair upgrades Terns Pharmaceuticals stock rating to Outperform - Investing.com
Terns Pharmaceuticals (TERN) Upgraded After Promising Clinical T - GuruFocus
Terns Pharmaceuticals stock soars on promising data for CML therapy By Investing.com - Investing.com Philippines
Terns Pharmaceuticals (TERN) Presents Promising Data from CARDINAL Trial - GuruFocus
Terns Pharmaceuticals stock soars on promising data for CML therapy - Investing.com
Terns Announces Abstract with Positive Clinical Data for TERN-701 in Relapsed/Refractory CML Selected for Oral Presentation at 67th ASH Annual Meeting - The Manila Times
Terns Pharmaceuticals Announces Positive Data from CARDINAL Trial - TradingView
Terns Announces Abstract with Positive Clinical Data for TERN-701 in Relapsed/Refractory CML ... - Bluefield Daily Telegraph
Will Terns Pharmaceuticals Inc. stock recover after recent dropPortfolio Return Report & Consistent Profit Trade Alerts - newser.com
Sector ETF performance correlation with Terns Pharmaceuticals Inc.Trade Entry Summary & Low Risk Entry Point Tips - newser.com
Applying Wyckoff theory to Terns Pharmaceuticals Inc. stockMarket Trend Review & High Conviction Buy Zone Picks - newser.com
Should you hold or exit Terns Pharmaceuticals Inc. nowTrade Ideas & Intraday High Probability Setup Alerts - newser.com
Real time breakdown of Terns Pharmaceuticals Inc. stock performanceQuarterly Performance Summary & Target Return Focused Stock Picks - newser.com
How hedge fund analytics apply to Terns Pharmaceuticals Inc. stockWeekly Investment Report & Long-Term Safe Return Strategies - newser.com
Is Terns Pharmaceuticals Inc. still worth holding after the dipJuly 2025 Highlights & AI Based Buy/Sell Signal Reports - newser.com
Advanced analytics toolkit walkthrough for Terns Pharmaceuticals Inc.Portfolio Value Report & Real-Time Market Trend Scan - newser.com
What Wall Street predicts for Terns Pharmaceuticals Inc. stock priceM&A Rumor & Long-Term Safe Return Strategies - newser.com
1.45%
0.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):